Medial journal The Lancet issued a correction on a large observational study that linked use of anti-malarial drug hydroxychloroquine with increased death risk in Covid-19 patients, after more than 100 scientists and medical professionals raised questions about integrity of data analysed in the study.
The study published on 22 May led the World Health Organization to temporarily suspend the trial of hydroxychloroquine on Covid-19 patients.
In the correction issued on Friday (29 May), Lancet said that one hospital self-designated as belonging to the Australasia continental designation should have been assigned to the Asian continental designation.
In their open letter to the authors of the study and the editor of Lancet, the scientists pointed out that "data from Australia are not compatible with government reports.".
The study was informed by data from healthcare data analytics company Surgisphere, the founder of which, Sapan Desai, is one of the four authors of the paper.
"There was no mention of the countries or hospitals that contributed to the data source and no acknowledgments to their contributions," the scientist said in their open letter.
"A request to the authors for information on the contributing centres was denied. Data from Australia are not compatible with government reports. Surgisphere have since stated this was an error of classification of one hospital from Asia. This indicates the need for further error checking throughout the database," they added.
The study analysed data from nearly 15,000 patients with Covid-19 and 81,000 controls.
The open letter lists 10 major concerns about statistical analysis and data integrity.
"The authors have not adhered to standard practices in the machine learning and statistics community. They have not released their code or data," the letter stated.
The Lancet is among the many signatories to a statement on data sharing for Covid-19 studies.
Surgisphere in a statement said that its data use agreements do not allow it to make some data public.
While issuing the correction, Lancet also said that "there have been no changes to the findings of the paper."
(This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.)
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.